MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Bridgebio Pharma Inc

Suletud

SektorTervishoid

33.02 -4.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.8

Max

34.45

Põhinäitajad

By Trading Economics

Sissetulek

-103M

-267M

Müük

3.2M

5.9M

Aktsiakasum

-1.374

Kasumimarginaal

-4,545.886

Töötajad

725

EBITDA

-95M

-235M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+58.87% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-30M

6.7B

Eelmine avamishind

37.06

Eelmine sulgemishind

33.02

Uudiste sentiment

By Acuity

12%

88%

21 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Bridgebio Pharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. sept 2024, 17:01 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12. sept 2024, 11:00 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Bridgebio Pharma Inc Prognoos

Hinnasiht

By TipRanks

58.87% tõus

12 kuu keskmine prognoos

Keskmine 54.92 USD  58.87%

Kõrge 95 USD

Madal 37 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Bridgebio Pharma Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

14

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

33.01 / 36.4Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

21 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.